RCC is usually recognized as a highly vascular tumor, so several drugs affecting VEGF signaling have been approved for the treatment of metastatic disease, and the improved understanding of the biology of RCC has contributed to the identification of two cellular signaling pathways that are relevant for molecular-targeting therapy, which are the VEGF pathway and the mTOR pathway [44]. Here, MTOR is linked to renal cell adenocarcinoma.